CMO
Chief Medical Officer
Clinical strategy, endpoint selection, KOL engagement, trial design, safety monitoring governance.
THE PLATFORM
Tell us your stage.
We build the team around the molecule.
Tribal·Bio turns a single prompt into a full, 24/7 autonomous biotech. Describe the asset and where you are. The platform asks the questions a seasoned development partner would — then assembles a synthetic team trained on thousands of regulatory and pre-clinical packages, ready to start work the moment you close the tab.
STEP 01 · INTAKE
It starts by asking the right questions.
You don't need a deck or a spec. Tell the platform where you are — "I have a pre-clinical small molecule targeting IL-17A, looking at psoriasis, about to start tox." It probes until it understands your asset, your stage, your capital, your timeline, your risk appetite. Only then does it build.
T
Tribal·Biointake
Welcome. Before we assemble your team — tell me, in your own words, what you're working on and where you are.
Y
You09:02
Small molecule inhibitor, IL-17A, pre-clinical. We have lead series but haven't started formal IND-enabling studies. Targeting moderate–severe psoriasis first.
T
Tribal·Biointake
Understood. A few more:
- What's your current PK profile and the lead compound's developability score?
- Is 505(b)(1) the target path, or would you consider a reformulation of an approved comparator?
- Do you have preferred CDMOs, or should I run the shortlist?
- Capital runway — are we optimising for speed to IND, speed to partnership, or speed to Phase I read-out?
Y
You09:04
505(b)(1). No CDMO preference. Optimising for speed to IND on 18 months of runway.
T
Tribal·Bioassembling
Good. I'm assembling a team optimised for speed-to-IND in a small-molecule dermatology program. Six synthetic employees, all trained on the relevant agency precedent. You'll see them in your console in a moment.
STEP 02 · FORMATION
A 24/7 autonomous team forms around the idea.
Every team is built from the ground up for your molecule, your stage, your pathway. They don't sleep. They don't forget. They hand work between each other the same way a real biotech would — and you see the decisions, not the chatter.
R
Regulatory Lead
Agency correspondence, pre-IND & IND authoring, 505(b)(1)/(2) strategy, FDA/EMA/MHRA precedent mapping.
C
CMC Lead
Manufacturing strategy, CDMO sourcing, formulation, stability, scale-up, process validation, supply planning.
T
Toxicology Lead
Tox strategy, species selection, 28-day & repeat-dose study design, bridging rationale, GLP oversight.
R
Researcher
Literature sweeps across PubMed and bioRxiv, target validation, competitor trial analysis, citation review.
M
Medicinal Chemistry
SAR review, lead optimisation strategy, patentability, synthetic route scoring, impurity profiling.
Q
Quality & QA
GxP posture, SOP authoring, QMS architecture, audit prep, vendor qualification, deviation handling.
B
Biostatistics
Sample size, SAP authoring, adaptive design scenarios, interim analyses, regulatory-grade statistical memos.
$
Commercial
TAM modelling, payer strategy, launch readiness, MSL narratives, partnership targeting, lifecycle planning.
O
Clinical Operations
Site selection, CRO oversight, protocol ops, recruitment modelling, IRB/ethics, monitoring plans.
F
Finance & Diligence
Program-level P&L, dilution modelling, investor-grade diligence packs, milestone pacing, term-sheet reads.
P
Program Lead
Owns the plan. Routes tasks across the team, escalates blockers, reports up to you — not around you.
24/7
runs overnight, across timezones
< 60s
to form a full team from a prompt
0
institutional memory lost between members
N+1
any new specialist spun up on demand
STEP 03 · OPTIMISATION
Trained on the data no frontier lab can buy.
Every synthetic employee is fine-tuned on a proprietary corpus — one we're still growing — of real pharmaceutical operating material. Not textbooks, not the open web. The tacit knowledge of people who have actually shipped drugs.
Every new biotech on Tribal adds to the corpus. Agents inherit the organisational wisdom of every prior program — so the team you spin up today is already better than the one we spun up last month.